What is Octreotide Acetate?
Symptomatic treatment to suppress or inhibit severe diarrhea and flushing associated with carcinoid tumors.
Long-acting suspension is used for long-term management of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors in patients in whom initial treatment with octreotide immediate-release injection has been shown to be effective and tolerated (designated an orphan drug by FDA for this use).
Acute management of potentially life-threatening hypotension associated with carcinoid crisis.
Prophylaxis of carcinoid crisis that might be precipitated by anesthesia, surgery, initiation of chemotherapy, or infection.
Vasoactive Intestinal Peptide-Secreting Tumors
Management of profuse watery diarrhea associated with vasoactive intestinal polypeptide (VIP)-secreting tumors.
Long-acting suspension is used for long-term management of profuse watery diarrhea associated with VIP-secreting tumors in patients who have been treated successfully with octreotide immediate-release injection (designated an orphan drug by FDA for this use).
Acromegaly
Treatment to reduce growth hormone (GH) and insulin-like growth factor I (IGF-I) blood concentrations in patients with acromegaly who have had inadequate responses to or are not candidates for surgical resection, pituitary irradiation, and bromocriptine mesylate (at maximally tolerated doses).
Long-acting suspension is used for long-term therapy in patients who are candidates for medical therapy and who have been treated successfully with immediate-release injection (designated an orphan drug by FDA for this use). Long-acting suspension may be used in patients who are not candidates for surgery or who have had an inadequate response to surgery or patients who have had a suboptimal response to radiation therapy.
Congenital Hyperinsulinism
Has been used in a limited number of neonates and infants to stabilize plasma glucose levels prior to pancreatectomy, to treat recurrent post-operative hypoglycemia, and as an alternative medical treatment to diazoxide for control of hypoglycemia.